TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02607241

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OCT-guided BRS implantation
Description: Implantation of a BRS using OCT to measure vessel size, choose BRS size and length and assess implantation results and the need of further postdilations

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFR-guided DCB-only PCI
Description: PCI performed under FFR guidance using following algorithm: (1) predilation followed by angiographic assessment of residual stenosis and dissections; (2) evaluate suitability for DCB-only, which is deemed feasible if the FFR \> 0.8, residual diameter stenosis \< 40% and no flow-limiting dissections are observed; (3) DCB dilation and (4) assessment of final results using FFR and QCA measurements. Provisional stenting is allowed only if the final PCI results are not acceptable (flow-limiting dissection, residual stenosis \> 40% or FFR \< 0.8).
Study: NCT03633630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amla
Description: Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days
Study: NCT02759107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Administered SC
Study: NCT03095027

Intervention type: DEVICE
Group type: OTHER
Intervention: FID122819 contact lenses
Description: Investigational spherical silicone hydrogel contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: FID122819 contact lenses
Description: Investigational spherical silicone hydrogel contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Stenfilcon A contact lenses
Description: Commercially available spherical silicone hydrogel contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Stenfilcon A contact lenses
Description: Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
Study: NCT03041675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Acupuncture group
Description: 47 participants receive 10 seconds of Laser Acupuncture(808nM/300mW) on acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Laser Acupuncture group
Description: The investigators apply the Laser Acupuncture pen (without pressing the Laser button) on other 47 participants' acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
Study: NCT00062023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid (Aspirin)
Description: Patients receive oral aspirin once daily for 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulindac
Description: Patients receive oral sulindac twice daily for 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodiol
Description: Patients receive oral ursodiol three times daily for 12 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sulindac Placebo
Description: Oral sulindac placebo twice daily.
Study: NCT04165655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Keep Achieving (KA)
Description: The 10-week group based activity programme will consist of 10 sessions each lasting 50 minutes.
Study: NCT02596373

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone Hydrochloride Liposome Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome Injection
Study: NCT02830347

Intervention type: DRUG
Intervention: Amoxicillin
Description: Extraction

Intervention type: PROCEDURE
Intervention: Extraction
Description: Extraction of third molars

Intervention type: PROCEDURE
Intervention: Extraction
Description: Extraction of third molars
Study: NCT02429713

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short-duration tourniquet
Description: Short-duration tourniquet group:inflate the tourniquet immediately before cement application and deflated after its hardening

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long-duration tourniquet
Description: Long-duration tourniquet group: inflate the tourniquet immediately before incision and deflated after the hardening of the cement
Study: NCT00539513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 3000 mg by mouth PO (1200 mg AM, 1800 mg PM), 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, 2 capsules PO AM, 3 capsules PO PM, 12 weeks
Study: NCT06408675

Intervention type: OTHER
Intervention: Visual Analog Scale (VAS), QOL (36-Item Short Form Survey (SF-36)), and Neck Disability Index (NDI) were used to assess pain, overall quality of life, functional disability respectively.
Description: Visual Analog Scale (VAS), QOL (36-Item Short Form Survey (SF-36)), and Neck Disability Index (NDI) were used to assess pain, overall quality of life, functional disability respectively.

Intervention type: OTHER
Intervention: Visual Analog Scale (VAS), QOL (36-Item Short Form Survey (SF-36)), and Neck Disability Index (NDI) were used to assess pain, overall quality of life, functional disability respectively.
Description: Visual Analog Scale (VAS), QOL (36-Item Short Form Survey (SF-36)), and Neck Disability Index (NDI) were used to assess pain, overall quality of life, functional disability respectively.
Study: NCT06167005

Intervention type: PROCEDURE
Intervention: Primary bariatric-metabolic surgery
Description: Primary bariatric-metabolic surgery

Intervention type: PROCEDURE
Intervention: Primary bariatric-metabolic surgery
Description: Primary bariatric-metabolic surgery

Intervention type: PROCEDURE
Intervention: Primary bariatric-metabolic surgery
Description: Primary bariatric-metabolic surgery

Intervention type: PROCEDURE
Intervention: Primary bariatric-metabolic surgery
Description: Primary bariatric-metabolic surgery
Study: NCT03166228

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline 0.9% Infusion Solution Bag
Description: 0.9% saline as distension medium as long as diathermy is not in use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1.5% Glycine only
Description: 1.5% Glycine alone during hysteroscopy as long as diathermy is in use
Study: NCT03431623

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CKD-11101(Darbepoetin alfa)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NESP(Darbepoetin alfa)
Study: NCT00175838

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: Hydroxyurea (or hydroxycarbamide) is an antineoplastic drug commonly used to treat haematological malignancies.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin is an anti-aggregating agent, and has been shown to reduce/alleviate minor ischaemic symptoms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin is an anti-aggregating agent, and has been shown to reduce/alleviate minor ischaemic symptoms.
Study: NCT02149628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Study: NCT03742687

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Heterogeneously Hypofractionated Radiotherapy
Description: A heterogeneous hypofractionated schedule for the treatment of high-risk locally advanced NSCLC patients in which the central idea is to decrease dose to normal tissue by ascribing a heterogeneous dose to the PTV. The dose to the periphery of the PTV as well as to the majority of lymph node targets is decreased compared to a standard treatment. The gross volume of the primary tumour and bulky lymph nodes receive mean doses of up to 66 Gy in 24 fractions, and thus receive a hypofractionated higher biological effective dose than standard 66 Gy in 33 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Heterogeneously Hypofractionated Radiotherapy
Description: A heterogeneous hypofractionated schedule for the treatment of high-risk locally advanced NSCLC patients in which the central idea is to decrease dose to normal tissue by ascribing a heterogeneous dose to the PTV. The dose to the periphery of the PTV as well as to the majority of lymph node targets is decreased compared to a standard treatment. The gross volume of the primary tumour and bulky lymph nodes receive mean doses of up to 66 Gy in 24 fractions, and thus receive a hypofractionated higher biological effective dose than standard 66 Gy in 33 fractions.
Study: NCT01202643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: One infusion of G-CSF 300 units administered by intrauterine infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: One intrauterine saline infusions of 1 cc
Study: NCT03944811

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: piezoelectric device
Description: crestal approach will be used to augment the maxillary sinus with simultaneous implant placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Summers technique
Description: Summers technique
Study: NCT02520141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Given IV
Study: NCT03410602

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full-mouth supragingival scaling
Description: Control group comprised of 15 patients who were treated with routine full-mouth supragingival scaling.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Full-mouth supragingival scaling
Description: Control group comprised of 15 patients who were treated with routine full-mouth supragingival scaling.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subgingival scaling
Description: Test group comprised of 15 patients who were treated with subgingival scaling only around all banded first molars.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Subgingival scaling
Description: Test group comprised of 15 patients who were treated with subgingival scaling only around all banded first molars.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subgingival irrigation
Description: Test group comprised of 15 patients who were treated with subgingival irrigation only around all banded first molars with 0.2% chlorhexidine gluconate solution (Trade name: HEXIDINE), an antiseptic - antiplaque agent.
Study: NCT04352049

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoxygenation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoxygenation
Study: NCT01657214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR125844
Description: Pharmaceutical form:Concentrate for solution~Route of administration: intravenous
Study: NCT03598140

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Citrate
Description: Sildenafil 60mg once (Group 1) or daily for 2 weeks (Group 2)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo once (Group 1) or daily for 2 weeks (Group 2)
Study: NCT02890511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed consent.
Study: NCT00095394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ
Description: Tablets, Oral, Irbesartan 150mg/HCTZ 12.5 mg, Once daily, 7 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan monotherapy
Description: Tablets, Oral, 150 mg, Once daily, 7 weeks.
Study: NCT02217449

Intervention type: OTHER
Intervention: Prediction of histology

Intervention type: OTHER
Intervention: Prediction of histology
Study: NCT01108263

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INTEGRA™ Flowable Matrix (Collagen)
Description: INTEGRA™ Flowable Wound Matrix is an advanced 3-D porous matrix comprised of granulated cross-linked bovine tendon collagen and glycosaminoglycan. It provides a scaffold for cellular invasion and capillary growth. The collagen and glycosaminoglycan mix is hydrated with saline and applied on the wound bed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INTEGRA™ Flowable Matrix (Collagen)
Description: INTEGRA™ Flowable Wound Matrix is an advanced 3-D porous matrix comprised of granulated cross-linked bovine tendon collagen and glycosaminoglycan. It provides a scaffold for cellular invasion and capillary growth. The collagen and glycosaminoglycan mix is hydrated with saline and applied on the wound bed.
Study: NCT01265940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib as add-on to vinflunine
Description: Patients will receive vinflunine standard regimen (intravenous infusion every three weeks) as specified per drug label plus additional pazopanib as daily oral medication. Doses of pazopanib will be escalated in 200 mg/d steps during phase I up to a maximum of 800 mg/d.~In Phase II the patients will be given pazopanib + vinflunine at maximum tolerated dose.
Study: NCT01211067

Intervention type: PROCEDURE
Intervention: Lichtenstein hernioplasty
Description: * Mesh hernioplasty~* Ultrapro mesh (Ethicon, Johnson \& Johnson)

Intervention type: PROCEDURE
Intervention: Lichtenstein hernioplasty
Description: * Mesh hernioplasty~* Ultrapro mesh (Ethicon, Johnson \& Johnson)

Intervention type: PROCEDURE
Intervention: Lichtenstein hernioplasty
Description: * Mesh hernioplasty~* Ultrapro mesh (Ethicon, Johnson \& Johnson)
Study: NCT00818636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing (in addition to group therapy as usual).
Description: Participants in the expressive writing condition write about their feelings about an issue of their choosing three times, for at least 20 minutes each time, during a two week period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expressive writing (in addition to group therapy as usual).
Description: Participants in the expressive writing condition write about their feelings about an issue of their choosing three times, for at least 20 minutes each time, during a two week period.
Study: NCT03869632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL-13027
Description: Daily doses by oral administration on each day of each 28 day cycle. Starting dose is 60mg, with escalation to 360mg, and subsequent dose escalation using a modified Fibonacci algorithm.
Study: NCT00474552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAM-315
Description: Multiple Ascending Doses of SAM-315 (treatment duration: 14 days): 0.2 mg; 0.5 mg; 1 mg; 2 mg;
Study: NCT00648973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg
Description: Three times daily: two diphenhydramine 25 mg capsules~Twice daily: one pseudoephedrine-matching placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 25 mg
Description: Three times daily: one diphenhydramine 25 mg capsule and one diphenhydramine-matching placebo capsule~Twice daily: one pseudoephedrine-matching placebo tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pseudoephedrine 120 mg
Description: Three times daily: two diphenhydramine-matching placebo capsules~Twice daily: one pseudoephedrine 120 mg tablet
Study: NCT04035473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules
Description: HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules~Oral paclitaxel capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules
Description: HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules~Oral paclitaxel capsules
Study: NCT01834469

Intervention type: DRUG
Group type: OTHER
Intervention: iv injection of ICG
Description: An iv injection will be performed for the ovarian cancer patient before the operation.
Study: NCT00966849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditional Cash Transfer
Description: Households will receive bimonthly payments of US$18 plus US$4 per child under 18 years living in the house up to a maximum of 3 children i.e. transfers will vary from $22 to $30. Households will only be given the cash if they comply with the following conditions:~* An application for a birth certificate must be made for all children under 18 years in the household who do not already have a birth certificate, including all newborn children within 3 months of birth.~* All children under 5 years in the household must be up-to-date with vaccinations.~* All children under 5 years must attend a growth monitoring clinic twice per year.~* All children 6-17 years in the household attended school at least 90% of days in the last month.~* At least one adult from each household attended at least 2 of the 3 most recent parenting skills classes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unconditional Cash Transfers
Description: Households will receive bimonthly payments of US$18 plus US$4 per child under 18 years living in the house up to a maximum of 3 children i.e. transfers will vary from $22 to $30. Households will not be required to comply with conditions in order to receive the cash.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Agricultural Package
Description: A standard agricultural package (e.g. seeds, fertiliser etc.) will be distributed in all study arms including the control arm as a gesture of goodwill to all those participating in the study.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Agricultural Package
Description: A standard agricultural package (e.g. seeds, fertiliser etc.) will be distributed in all study arms including the control arm as a gesture of goodwill to all those participating in the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Agricultural Package
Description: A standard agricultural package (e.g. seeds, fertiliser etc.) will be distributed in all study arms including the control arm as a gesture of goodwill to all those participating in the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parenting Skills Classes
Description: 2-3 parenting skills classes will be held annually in each study cluster.

Intervention type: OTHER
Group type: OTHER
Intervention: Parenting Skills Classes
Description: 2-3 parenting skills classes will be held annually in each study cluster.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parenting Skills Classes
Description: 2-3 parenting skills classes will be held annually in each study cluster.
Study: NCT04083599

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN1042
Description: Intravenous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN1042
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous
Study: NCT00731289

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone
Description: one intraarticular injection of triamcinolone 1 ml (Volon A10®, 10mg triamcinolone acetonide, 10mg/ml)~antiinflammatory intervention
Study: NCT00715078

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sipuleucel-T
Description: Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sipuleucel-T
Description: Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sipuleucel-T
Description: Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)
Study: NCT00933309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25 mg tablets orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25 mg tablets orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avandamet
Description: Beginning dose 2 mg rosiglitazone with 500 mg metformin hydrochloride (2mg/500 mg) tablets taken orally once a day
Study: NCT04083599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous
Study: NCT03232801

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based multicomponent intervention
Description: A group-based, multicomponent behavioral intervention rooted in mindfulness

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: general health education group
Description: A general health and aging education group
Study: NCT01751867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine at 15 mg/m2
Description: Decitabine will be given at a dose of 15 mg/m2 as a continuous intravenous infusion within a 3-hour intravenous infusion, repeated every 8 hours for 3 consecutive days.The total dose per day is 45 mg/m2; The total dose per course is 135 mg/m2. Cycles will be repeated every 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine at 20 mg/m2
Description: Decitabine will be given at a dose of 20 mg/m2 as 1-hour IV infusion once daily on Days 1 through 5, of a 4-week treatment cycle.